Net Income

A new health tech platform is launching to turn movement into trackable, reimbursable medicine, bridging the gap between doctor's advice and patient action.

With a new CEO and private equity backing, meQuilibrium is betting its AI platform can solve the billion-dollar burnout and mental health crisis.

Emerald Holding reports a 16% revenue jump but a $30.7M net loss, driven by acquisition costs, as the board considers a potential company sale.

At SXSW, Reckitt Catalyst and Serena Williams unveil a new cohort of U.S. entrepreneurs tackling America's deep-rooted healthcare access crisis.

The German biotech firm secured its Nasdaq listing, but a near-total investor redemption leaves its cancer-drug pipeline with less than $1M in trust funds.

A landmark study reveals an accelerated brain stimulation protocol can treat major depression in six days, offering rapid relief and dismantling barriers to care.

China's BABI launches a 4-in-1 sunscreen using patented tech and Nobel-inspired science to solve irritation, feel, and protection gaps.

The $759B nutrition market in Asia is no longer just about health. Consumers now demand emotional benefits, natural ingredients, and ultimate convenience.

The grill maker's 1-for-50 reverse stock split aims to avoid delisting, but deep financial woes and historical data suggest a tough road ahead.

The midstream firm is refinancing debt and buying back preferred units, aiming for a simpler, more flexible financial future. What does this mean for NGL?

The organic kids' food brand reports impressive sales and a strong IPO, but investors are keenly watching its strategy for long-term profitability.

Universal Electronics is restructuring for profitability amid falling sales, raising questions about the future of the connected home market.

Lucara Diamond Corp. finalizes a massive financing package for its Karowe mine expansion, averting a crisis but taking on costly debt to secure its future.

After a strategic pivot and R&D setbacks, Korro Bio secures an $85M lifeline to advance its novel RNA-editing drug for rare metabolic diseases.

Hydrafacial's parent company posts a massive jump in profitability for 2025, but slowing device sales and cautious guidance raise questions for 2026.

Maker's Pride is closing two Midwest facilities as part of a strategic shift to automation, leaving communities in Utah and Minnesota facing an uncertain future.

Amid a complex healthcare market, The Ensign Group will outline its aggressive growth and operational playbook for investors at the upcoming Oppenheimer conference.

A manufacturing flaw in some Omnipod 5 insulin pods has caused serious health issues, prompting a company response and raising questions about device safety.

BRC Group Holdings announced a major debt reduction, but a history of late filings, shareholder dilution, and high-risk bets cast a shadow on its recovery.

With a new strategic finance leader, MATEREAL signals a shift from R&D to aggressive commercialization of its 'drop-in' AI-enabled bio-polymers.